搜索优化
English
全部
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
搜索
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
18 天
摩根大通给予Maze Therapeutics增持评级,目标价30美元
摩根大通的乐观展望还源于目标人群的广度、潜在定价策略、市场份额前景以及MZE829成功的可能性,他们认为这些因素都可能使该药物成为重磅产品。他们认为这些因素可能成为推动Maze股价上涨的杠杆。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Senate passes funding bill
Sworn in as Canada's PM
Child abuse images sentence
Strikes deal with DOGE
Texas measles outbreak
Plane engine catches fire
March megastorm
Man hit by motorcade, dies
Top intelligence agency visit
Hamas to release hostage
Coffee creamer recall
Consumer sentiment drops
Felony gun possession arrest
ISIS leader killed in Iraq
‘Ted Lasso’ is coming back
Second protester arrested
Influencer leaves Australia
Influential WY senator dies
To cut 2,000+ jobs
Syed formally resentenced
Senate confirmation hearing
Legendary sportswriter dies
Visits DOJ for speech
US expels SA ambassador
Gold rises to new heights
Court lifts Trump's DEI block
Permanently shuts route
Wins longest-ever Iditarod
Pleads not guilty
Laceration hazard recall
反馈